SLGC Stock Price, SomaLogic, Inc. Quote, Chart

Market Summary

USD2.10

Market Closed

SLGC Stock Price

View Fullscreen

SLGC RSI Chart

SLGC Valuation

Market Cap

395.0M

Price/Earnings (Trailing)

-3.03

Price/Sales (Trailing)

4.83

EV/EBITDA

-0.73

Price/Free Cashflow

-3.26

SLGC Price/Sales (Trailing)

SLGC Profitability

EBT Margin

-159.08%

Return on Equity

-26.25%

Return on Assets

-23.07%

Free Cashflow Yield

-30.69%

SLGC Fundamentals

SLGC Revenue

Revenue (TTM)

81.7M

Rev. Growth (Yr)

-47.14%

Rev. Growth (Qtr)

7.72%

SLGC Earnings

Earnings (TTM)

-130.4M

Earnings Growth (Yr)

32.74%

Earnings Growth (Qtr)

10.56%

Breaking Down SLGC Revenue

Last 7 days

-17%

Last 30 days

-25.8%

Last 90 days

-0.9%

Trailing 12 Months

-16.3%

How does SLGC drawdown profile look like?

SLGC Financial Health

Current Ratio

17.79

SLGC Investor Care

Shares Dilution (1Y)

0.29%

Diluted EPS (TTM)

-0.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	95.1M	101.4M	81.7M	0
2022	85.7M	80.1M	101.8M	97.7M
2021	62.3M	68.8M	75.2M	81.6M
2020	0	0	0	55.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of SomaLogic, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 05, 2024	post richard a	back to issuer	-	-	-57,430	-
Jan 05, 2024	roelke alison marie	back to issuer	-	-	-17,143	chief people officer
Jan 05, 2024	barchi robert	back to issuer	-	-	-7,630	-
Jan 05, 2024	casdin eli	back to issuer	-	-	-6,800,000	-
Jan 05, 2024	casdin eli	back to issuer	-	-	-2,472,270	-
Jan 05, 2024	gutierrez ruben	back to issuer	-	-	-21,027	general counsel
Jan 05, 2024	casdin eli	back to issuer	-	-	-10,132,000	-
Jan 05, 2024	cox troy	back to issuer	-	-	-78,430	-
Jan 05, 2024	margulies anne h.	back to issuer	-	-	-10,132,000	-
Jan 05, 2024	margulies anne h.	back to issuer	-	-	-2,472,270	-

Which funds bought or sold SLGC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 19, 2024	Sumitomo Mitsui Trust Holdings, Inc.	sold off	-100	-21,004,100	-	-%
Apr 19, 2024	Evolution Wealth Advisors, LLC	sold off	-100	-27,830	-	-%
Apr 18, 2024	ARK Investment Management LLC	sold off	-100	-36,032,200	-	-%
Apr 17, 2024	Evergreen Private Wealth LLC	sold off	-100	-34,985	-	-%
Apr 05, 2024	CWM, LLC	sold off	-100	-21,000	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	40.00	40.00	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.36	1,579,930	20,498,400	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	89.48	2,589,630	5,164,240	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	9,793	190,071	-%
Feb 26, 2024	Virtu Financial LLC	reduced	-30.18	-9,000	26,000	-%

Are Funds Buying or Selling SLGC?

Are funds buying SLGC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SLGC

No. of Funds

Unveiling SomaLogic, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 29, 2024	blackrock inc.	6.1%	11,548,774	SC 13G/A
Jan 29, 2024	ark investment management llc	7.55%	14,241,979	SC 13G/A
Jan 09, 2024	cmls holdings ii llc	0%	0	SC 13D/A
Feb 14, 2023	gold lawrence marshall	1.9%	3,627,197	SC 13G/A
Feb 03, 2023	blackrock inc.	5.5%	10,268,281	SC 13G
Dec 14, 2022	cmls holdings ii llc	5.8%	11,146,669	SC 13D/A
Feb 11, 2022	gold lawrence marshall	5.04%	9,133,066	SC 13G

Recent SEC filings of SomaLogic, Inc.

View All Filings

Date Filed	Form Type	Document
Jan 29, 2024	SC 13G/A	Major Ownership Report
Jan 29, 2024	SC 13G/A	Major Ownership Report
Jan 16, 2024	15-12G	15-12G

Peers (Alternatives to SomaLogic, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	461.9B	371.6B	1.38%	2.78%	20.64	1.24	14.64%	11.24%
CI	103.1B	195.3B	-0.38%	37.81%	19.18	0.53	8.17%	-20.79%
CVS	87.8B	357.8B	-11.69%	-4.78%	10.51	0.25	10.95%	93.52%
HCA	80.7B	65.0B	-7.20%	12.71%	15.4	1.24	7.86%	-7.11%
CNC	40.2B	154.0B	-3.58%	14.01%	14.86	0.26	6.54%	124.79%
DVA	11.2B	12.1B	-7.92%	53.74%	16.21	0.92	4.57%	23.40%
UHS	10.9B	14.3B	-12.49%	15.68%	15.2	0.76	6.59%	6.24%
MID-CAP
CHE	9.1B	2.3B	-6.50%	6.12%	33.31	4.01	6.06%	9.17%
ACHC	6.5B	2.9B	-8.97%	-3.82%	-298.84	2.21	12.20%	-107.93%
AMN	2.2B	3.8B	-13.83%	-35.23%	10.24	0.57	-27.73%	-52.50%
AMEH	2.1B	1.4B	-10.13%	1.91%	34.08	1.49	21.19%	34.42%
SMALL-CAP
ADUS	1.6B	1.1B	-3.82%	-13.66%	25.23	1.49	11.31%	35.83%
BKD	1.2B	3.0B	1.73%	53.19%	-6.49	0.41	6.74%	20.73%
BEAT	50.8M	-	-10.91%	-11.71%	-3.47	-	-	-12.94%
AMS	18.9M	21.3M	12.41%	5.40%	35.51	0.89	8.00%	-62.25%

SomaLogic, Inc. News

Latest updates

SomaLogic, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	7.7%	22,048,000	20,468,000	20,379,000	18,829,000	41,713,000	14,144,000	22,980,000	22,994,000	19,992,000	19,780,000	18,860,000	16,546,500	14,233,000
Operating Expenses	-2.8%	50,130,000	51,563,000	60,572,000	73,310,000	82,325,000	61,525,000	56,267,000	51,352,000	44,998,000	31,408,000	27,172,000	-	20,134,000
S&GA Expenses	-19.3%	23,880,000	29,573,000	34,189,000	40,038,000	49,511,000	36,812,000	30,815,000	29,697,000	20,632,000	14,833,000	12,809,000	-	8,337,000
R&D Expenses	-3.3%	10,458,000	10,815,000	14,067,000	22,589,000	19,419,000	17,636,000	13,800,000	11,192,000	15,596,000	8,590,000	8,118,000	-	6,884,000
EBITDA Margin	-12.5%	-1.50	-1.34	-1.42	-1.08	-0.82	-1.06	-0.99	-1.02	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	2,000	148,000	1,174,000	-	1,595,000
Income Taxes	23800.0%	478,000	2,000	2,000	-116,000	-600,000	5,000	3,000	-	-	-	-	-	-
Earnings Before Taxes	12.5%	-21,679,000	-24,770,000	-34,200,000	-49,358,000	-33,560,000	-22,980,000	-3,976,000	-	-41,419,000	-	-	-	-
EBT Margin	-13.7%	-1.59	-1.40	-1.47	-1.12	-0.86	-1.09	-1.02	-1.07	-	-	-	-	-
Net Income	10.6%	-22,157,000	-24,772,000	-34,202,000	-49,251,000	-32,942,000	-22,985,000	-3,979,000	-23,307,000	-41,419,000	-13,337,000	-9,484,000	-8,914,000	-7,483,000
Net Income Margin	-14.6%	-1.60	-1.39	-1.47	-1.12	-0.82	-1.14	-0.96	-1.07	-0.97	-0.57	-0.72	-0.95	-
Free Cashflow	19.9%	-21,736,000	-27,123,000	-44,307,000	-28,053,000	-39,417,000	-32,135,000	-6,279,000	-18,224,000	-17,880,000	-3,504,000	-4,083,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-3.5%	565	586	614	647	688	686	713	706	719	277	278	242
Current Assets	-4.3%	494	516	547	582	621	659	690	692	707	1.00	2.00	232
Cash Equivalents	-13.8%	306	355	439	422	380	418	438	440	469	47.00	85.00	165
Inventory	-8.2%	14.00	15.00	15.00	14.00	18.00	21.00	14.00	11.00	11.00	-	-	7.00
Net PPE	-2.7%	18.00	19.00	20.00	20.00	20.00	16.00	12.00	10.00	6.00	-	-	4.00
Goodwill	0%	10.00	10.00	10.00	10.00	10.00	-	-	-	-	-	-	-
Liabilities	-3.2%	68.00	71.00	79.00	85.00	86.00	79.00	96.00	94.00	93.00	68.00	52.00	56.00
Current Liabilities	-11.8%	28.00	32.00	39.00	43.00	43.00	35.00	28.00	29.00	22.00	0.00	0.00	18.00
Shareholder's Equity	-3.6%	497	515	535	563	603	607	617	612	626	174	181	186
Retained Earnings	-3.3%	-689	-667	-642	-608	-558	-525	-502	-498	-475	-43.28	-26.41	-411
Additional Paid-In Capital	0.3%	1,186	1,183	1,178	1,171	1,162	1,134	1,121	1,111	1,101	48.00	31.00	597
Accumulated Depreciation	8.1%	23.00	21.00	20.00	18.00	17.00	16.00	16.00	15.00	-	-	-	-
Shares Outstanding	0.3%	189	188	188	188	183	183	182	182	122	115	114	114

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	18.6%	-21,365	-26,237	-43,045	-26,608	-37,785	-30,361	-5,915	-17,938	-15,821	-2,734	-3,891	-	-
Share Based Compensation	-7.0%	4,004	4,307	7,183	8,584	16,894	9,460	8,671	7,715	12,684	4,764	3,252	-	-
Cashflow From Investing	52.4%	-27,579	-57,972	55,279	67,805	512	6,858	7,367	-11,682	-98,149	3,494	-75,682	-	-
Cashflow From Financing	-100.0%	-	250	172	300	-	3,643	1,242	403	535,548	-39,077	617	-	-

SLGC Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue
Collaboration revenue	$ 763	$ 763	$ 2,288	$ 2,288
Total revenue	22,048	41,713	62,895	78,837
Operating expenses
Research and development	10,458	19,419	35,340	50,855
Selling, general and administrative	23,880	49,511	87,642	116,024
Transaction costs	4,157	1,725	4,157	2,839
Total operating expenses	50,130	82,325	162,265	200,117
Loss from operations	(28,082)	(40,612)	(99,370)	(121,280)
Other income
Interest income and other, net	6,087	2,421	16,810	3,468
Change in fair value of warrant liabilities	316	3,371	1,896	30,547
Change in fair value of earn-out liability	0	1,260	15	26,749
Total other income	6,403	7,052	18,721	60,764
Net loss before income tax (provision) benefit	(21,679)	(33,560)	(80,649)	(60,516)
Income tax (provision) benefit	(478)	618	(482)	610
Net loss	(22,157)	(32,942)	(81,131)	(59,906)
Other comprehensive income (loss)
Net unrealized (loss) gain on available-for-sale securities	(27)	(13)	501	(874)
Foreign currency translation loss	(4)	(14)	(2)	(28)
Total other comprehensive (loss) income	(31)	(27)	499	(902)
Comprehensive loss	$ (22,188)	$ (32,969)	$ (80,632)	$ (60,808)
Net loss per share, basic (in usd per share)	$ (0.12)	$ (0.18)	$ (0.43)	$ (0.33)
Net loss per share, diluted (in usd per share)	$ (0.12)	$ (0.18)	$ (0.43)	$ (0.33)
Weighted-average shares outstanding used to compute net loss per share, basic (in shares)	187,070,510	184,407,874	186,780,699	183,209,213
Weighted-average shares outstanding used to compute net loss per share, diluted (in shares)	187,070,510	184,407,874	186,780,699	183,209,213
Assay services revenue
Revenue
Revenue	$ 17,866	$ 17,574	$ 52,882	$ 47,305
Operating expenses
Cost of revenue	9,994	11,264	31,353	29,215
Product revenue
Revenue
Revenue	3,418	1,051	7,513	2,218
Operating expenses
Cost of revenue	1,641	406	3,773	1,184
Other revenue
Revenue
Revenue	$ 1	$ 22,325	$ 212	$ 27,026

SLGC Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 305,571	$ 421,830
Investments	148,239	117,758
Accounts receivable, net	20,730	17,006
Inventory	13,884	13,897
Deferred costs of services	379	1,337
Prepaid expenses and other current assets	5,302	9,873
Total current assets	494,105	581,701
Non-current inventory	11,119	4,643
Accounts receivable, net of current portion	8,681	9,284
Property and equipment, net of accumulated depreciation and amortization of $23,126 and $17,899 as of September 30, 2023 and December 31, 2022, respectively	18,172	19,564
Other long-term assets	5,872	5,083
Intangible assets	16,700	16,700
Goodwill	10,399	10,399
Total assets	565,048	647,374
Current liabilities
Accounts payable	11,458	16,794
Accrued liabilities	10,829	20,678
Deferred revenue	3,074	3,383
Other current liabilities	2,420	2,477
Total current liabilities	27,781	43,332
Warrant liabilities	2,317	4,213
Deferred revenue, net of current portion	30,944	31,732
Other long-term liabilities	7,267	5,539
Total liabilities	68,309	84,816
Commitments and contingencies (Note 10)
Stockholders’ equity
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding at September 30, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 600,000,000 shares authorized; 188,662,349 and 187,647,973 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	19	19
Additional paid-in capital	1,186,420	1,171,122
Accumulated other comprehensive income (loss)	(14)	(513)
Accumulated deficit	(689,686)	(608,070)
Total stockholders’ equity	496,739	562,558
Total liabilities and stockholders’ equity	$ 565,048	$ 647,374

About SomaLogic, Inc.

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.

CEO	Mr. Adam Taich
WEBSITE	somalogic.com
INDUSTRY	Healthcare Plans
EMPLOYEES	451

SomaLogic, Inc. Frequently Asked Questions

What is the ticker symbol for SomaLogic, Inc.? What does SLGC stand for in stocks?

SLGC is the stock ticker symbol of SomaLogic, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SomaLogic, Inc. (SLGC)?

As of Fri Jan 05 2024, market cap of SomaLogic, Inc. is 394.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SLGC stock?

You can check SLGC's fair value in chart for subscribers.

What is the fair value of SLGC stock?

You can check SLGC's fair value in chart for subscribers. The fair value of SomaLogic, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SomaLogic, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SLGC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SomaLogic, Inc. a good stock to buy?

The fair value guage provides a quick view whether SLGC is over valued or under valued. Whether SomaLogic, Inc. is cheap or expensive depends on the assumptions which impact SomaLogic, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLGC.

What is SomaLogic, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jan 05 2024, SLGC's PE ratio (Price to Earnings) is -3.03 and Price to Sales (PS) ratio is 4.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLGC PE ratio will change depending on the future growth rate expectations of investors.